Short answer: ABM is the right motion for medical device and digital health companies because the buying decision is spread across a crowd, not a champion: clinicians, value analysis committees, supply-chain and procurement, hospital IT and security, biomedical engineering, and finance each hold a veto, and the contract itself often flows through an IDN standardization decision or a GPO agreement above the individual hospital. Lead-based marketing produces a form-fill from one of those roles and misses the other eight. Account-based marketing targets the whole committee inside a named health system, personalizes the case for each role, and stays on through a cycle that routinely runs twelve to twenty-four months. You can buy that motion from a specialist agency, but for most MedTech and health-IT teams an AI-native platform run in-house delivers more pipeline per dollar, because your real problem is identifying which accounts are already researching you, not renting campaign hours.
Key takeaways
- Medical device and digital health purchases are committee sales with a regulatory overlay: the clinician who wants the product is rarely the person who signs, and the person who signs answers to a value analysis committee, procurement, and often a group purchasing organization.
- The account you are really selling to may be an Integrated Delivery Network (IDN) rather than a single hospital, and the price may already be set by a GPO contract with Vizient, Premier, or HealthTrust. Your ABM account list has to reflect that hierarchy.
- Connected devices and health-IT platforms now clear a security and interoperability gauntlet (hospital IT, CISO, EHR integration, HITRUST or SOC 2) that traditional device reps never had to sell into. That is a distinct buying center your program must address.
- Regulated marketing claims constrain the content, not the channel. You can run full-funnel ABM as long as promotional claims stay inside cleared or approved indications and you avoid off-label promotion.
- Conferences (HIMSS, MD&M, AAMI, RSNA, specialty society meetings) still anchor MedTech demand, and ABM is how you turn a badge scan into a multi-threaded account play instead of a cold follow-up.
- Whether an agency or your own team runs it, keep the account list, intent signal, and engagement history in systems you own. In a long, audit-minded sale, that continuity is the asset.
Why ABM fits medical device and digital health GTM
Every vertical claims a complex sale. MedTech and digital health actually earn the label, because the decision is structurally distributed across roles that disagree about what matters. A surgeon evaluates a device on clinical outcomes and feel in the hand. A value analysis committee evaluates the same device on total cost, evidence quality, and whether it displaces an existing contract. Supply chain evaluates it on standardization and vendor risk. For anything connected, hospital IT and security evaluate it on integration and attack surface. Finance evaluates the capital line. No single message wins all of them, which is precisely the problem account-based marketing exists to solve.
The buying committee is a crowd, not a champion
A clinical champion is necessary and nowhere near sufficient. Getting a surgeon to love your device gets you onto a value analysis committee agenda, where a different audience asks economic and safety questions your clinical deck never anticipated. Digital health is no gentler: a care-management or patient-engagement platform has to satisfy the clinical sponsor, the CMIO, the EHR integration team, the security reviewer, and a procurement lead who has seen a dozen point solutions fail to renew. ABM lets you map those roles per account and put a role-specific argument in front of each one, instead of hoping a single landing page speaks to all of them at once.
The cycle outlives any campaign calendar
Device and health-IT deals do not close on a quarterly rhythm. Capital equipment, EHR-adjacent software, and enterprise device standardization commonly take a year or more, and the committee composition shifts along the way as new stakeholders are pulled in. A burst campaign that runs for six weeks and stops is invisible for the eleven months that matter. The motion that compounds is always-on: keep the account's web experience relevant to whoever is currently engaged, adjust as the committee widens, and feed every touch back to sales. This is the same committee-and-cycle logic we cover for the broader industry in the healthcare ABM agency guide, applied to the device and MedTech shape specifically.
The account above the account: IDNs and GPOs
The single biggest targeting mistake in MedTech ABM is treating a hospital as the account when the real buying unit sits above it. Many hospitals belong to an Integrated Delivery Network that standardizes purchasing across its facilities, so a win at one site can propagate, and a loss at the network level can lock you out of all of them. Above that, group purchasing organizations negotiate the contracts that individual facilities buy against. If you are not on the relevant GPO agreement, a clinician who loves your product may still be told it is off-contract.
For your account list, that means three practical adjustments. First, build accounts at the IDN or health-system parent level, not just the individual hospital, and roll site-level engagement up to the parent. Second, tag which of your target systems buy primarily through Vizient, Premier, or HealthTrust, because contract status changes the message from "why us" to "we are already on your agreement." Third, treat GPO and IDN supply-chain leaders as first-class ABM personas, not an afterthought behind the clinical champion. The committee sale and the contract layer are two different problems, and a serious program addresses both.
Regulated claims and connected-device security change the content rules
Medical device and digital health marketing is regulated, but the constraint lands on claims, not on running ABM at all. Promotional content has to stay inside the cleared or approved indications for the product, avoid off-label promotion, and carry appropriate context for any performance claim. That shapes what your assets say. It does not stop you from identifying accounts, personalizing web experiences by role, or sequencing outreach. Teams that conflate "our claims are regulated" with "we cannot do modern demand generation" leave pipeline on the table. If your program touches drug promotion specifically, that is a different rulebook, and our pharma ABM agency guide covers the FDA-promotion side.
The newer wrinkle is security. Any connected device or software platform now has to clear a hospital IT and security review that legacy device reps never faced. Buyers ask about premarket cybersecurity, a software bill of materials, patch commitments, EHR interoperability, and third-party attestations like HITRUST or SOC 2. That review is a full buying center with its own objections, and your ABM content library needs a security-and-integration track aimed at CISOs and IT architects, not just clinical and economic evidence for the VAC. For health-IT vendors especially, this track is often where deals stall, which is why we treat it as its own motion in the ABM for healthcare IT playbook.
Skip the manual work
Abmatic AI runs targets, sequences, ads, meetings, and attribution autonomously. One platform replaces 9 tools.
See the demo →Account-based plays that move device and health-IT deals
The theory is only useful if it turns into specific plays. Here is what account-based execution looks like for each side of this market.
For device manufacturers
- Value analysis committee kit, delivered by account. Build a package the VAC actually needs: clinical evidence summary, total-cost-of-ownership model, and a contract-status note showing GPO alignment. Personalize the web experience so a target system's committee lands on that package, not your generic product page.
- Multi-thread the site, not just the inbox. When an account is on your website, show the surgeon a clinical-outcomes narrative and the supply-chain lead a standardization-and-contract narrative from the same visit. That role-aware personalization is the core ABM move, and it is invisible to competitors who only run email.
- Turn conference badge scans into account plays. A scan at MD&M, AAMI, or a specialty society meeting is one contact inside a committee of ten. Enroll the whole account, not the one badge, and follow up with role-specific proof rather than a single templated thanks-for-visiting email.
For health-IT and digital health vendors
- Run a security-and-integration track in parallel with the clinical case. Give the CISO and integration team their own evidence set (SOC 2, HITRUST, interoperability documentation) early, because a stalled security review kills more digital health deals than a weak clinical story does.
- De-anonymize research-mode buyers. CMIOs, clinical-ops leaders, and hospital IT architects research quietly and rarely fill out a form. Identifying which health systems are on your site without a form-fill is often the difference between a pipeline and a guess. We go deeper on this in visitor ID for healthcare tech companies.
- Sequence by committee stage, not by lead score. Match the message to where the account is: clinical sponsor early, security and integration mid-cycle, procurement and finance late. A single nurture track that ignores committee stage feels irrelevant to whoever is currently driving.
Agency versus in-house versus platform
Once the plays are clear, the real decision is who runs them. Three models exist, and they are not equivalent for this vertical.
| Dimension | Specialist agency retainer | In-house on point tools | In-house on an AI-native platform |
|---|---|---|---|
| Best when | No internal ABM skill; need MedTech-specific strategy fast | Large team with budget for many tools and headcount to run them | Lean team that needs enterprise-grade execution without agency hours |
| Cost shape | Monthly retainer plus media and platform fees on top | Stacked subscriptions across 10-plus tools plus salaries | One platform license replacing much of the stack |
| Account visibility | Owned by the agency; you get reports | Depends on which identity tool you bought | First-party visitor de-anonymization built in |
| Fits the long cycle | Campaign calendars, not always-on | Yes, if you integrate the tools yourself | Always-on personalization across the whole cycle |
| Auditability | Lives in the agency's systems | Scattered across tools | Segment-and-experience log you own |
Retainer bands for healthcare-specialist agencies, and when the premium is worth paying, are covered in detail in the healthcare ABM agency guide. The short version for MedTech and digital health: pay for real IDN and GPO data, provider-org maps, and health-system relationships if the agency genuinely brings them, and refuse to pay a premium for healthcare logos on a slide.
Where an AI-native platform lets a lean team run enterprise ABM
The reason the platform column wins for most device and digital health teams is that your hardest problem is not creative, it is visibility and coordination across a distributed committee over a long cycle. Those are execution problems that AI handles well and that agency hours handle expensively.
Abmatic AI is built for exactly this shape. It starts with first-party visitor de-anonymization, so you see which health systems, IDNs, and vendors are researching you before anyone fills out a form, which is the signal MedTech and health-IT sellers usually lack. It then personalizes the website per account and per role, so a value analysis committee sees economic and contract evidence while a clinical sponsor sees outcomes, from the same traffic. Agentic Workflows, Agentic Outbound, and Agentic Chat run the plays with AI instead of retainer hours, sequencing outreach by committee stage and keeping the account warm across the full cycle. Engagement flows back into Salesforce, HubSpot, or Marketo so sales works a live account, not a stale list. In practice, that collapses a stack of roughly fifteen point tools into one platform on a shared identity graph, which is how a lean MedTech or digital health team runs a program that looks enterprise-grade. If you want to see the in-house version before you sign a retainer, book a demo.
Frequently Asked Questions
What makes ABM different for medical device companies versus other B2B?
Two things: the committee is unusually large and cross-functional (clinicians, value analysis committee, supply chain, hospital IT, finance), and the buying unit often sits above the individual hospital in an IDN or a GPO contract. Your account list, personas, and messaging all have to reflect that hierarchy, which generic B2B ABM advice usually ignores.
Do regulated claims stop us from running full-funnel ABM?
No. Regulation constrains what your promotional content can claim, not whether you can identify accounts, personalize web experiences, or sequence outreach. Keep claims inside cleared or approved indications and avoid off-label promotion, and you can run modern account-based marketing. Drug promotion is a separate rulebook covered in the pharma ABM agency guide.
How do we run ABM against IDNs and GPOs?
Build accounts at the IDN or health-system parent level and roll site-level engagement up to it, tag which target systems buy through Vizient, Premier, or HealthTrust so you know your contract status going in, and treat supply-chain and GPO leaders as first-class personas alongside the clinical champion. The clinical love and the contract access are two different sales.
Why do digital health deals stall in security review?
Because a connected platform now clears a hospital IT and security gauntlet (premarket cybersecurity, software bill of materials, EHR interoperability, HITRUST or SOC 2) that clinical champions cannot answer for. If your ABM program has no dedicated security-and-integration track aimed at CISOs and IT architects, deals sit in that review indefinitely.
Should a lean MedTech team use an agency or a platform?
If you lack any internal ABM skill and need MedTech-specific strategy immediately, a specialist agency can bootstrap you. For most teams, the harder problem is visibility and coordination across a long committee sale, which an AI-native platform like Abmatic AI handles in-house for less than a retainer, while keeping the account list, intent data, and audit trail in systems you own.
